Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis

Inclusion Criteria: * Those who fall under Kellgren-Lawrence grade 2 to 3 according to the criteria in accordance with ACR guidelines and X-ray findings used within 12 months * VAS score exceeding 50mm * An adult male and female over 50 years of age * Preservative therapy Glucosamine chondroitin sulfate/physiological therapy and rehabilitation exercises, and joint injections of hyaluronic acid for more than 12 weeks * A person who agrees to maintain existing medication treatments during the clinical trial period but does not receive additional medication or new conservative treatments for knee osteoarthritis pain management. Exclusion Criteria: * A locally infected patient * A person whose life expectancy is less than six months * A person with symptoms of lower extremities that are considered secondary to atherosclerosis or arterial vascular disease (ex: claudication ischemic rest pain) * A person diagnosed with rheumatism or infectious arthritis * A person who has undergone knee arthroplasty * A person who has not had knee microfracture surgery for more than 10 years * INR 2.5 or less than 30,000 platelets * Anaphylaxis-causing iodine allergy * Patients with renal dysfunction or impaired renal function who have been diagnosed with less than 45 GFR (eGFR) within the last 60 days * Those who have a taboo on MR videos * Pregnant women * Other cases where it is deemed inappropriate to participate in this clinical trial at the discretion of the researcher